Psen1 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Psen1 Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [1]
Presenilin 1 (PSEN1) is the most common cause of autosomal dominant familial Alzheimer's disease, with over 200 pathogenic mutations identified. PSEN1 encodes the catalytic subunit of γ-secretase, and mutations alter amyloid-beta production. [2]
Presenilin 1 is the catalytic core of γ-secretase:
| Mutation | Age of Onset | Aβ Effect |
|---|---|---|
| M146L | ~45 years | Aβ42 ↑ |
| L286V | ~50 years | Aβ42 ↑↑ |
| A246E | ~50 years | Aβ42 ↑ |
| H163R | ~55 years | Aβ42 ↑ |
| A431V | ~55 years | Aβ42 ↑ |
PSEN1 mutation carriers often included in prevention trials
DIAN-TU: Dominantly Inherited Alzheimer Network Trials
API: Alzheimer's Prevention Initiative
PSEN2 Mutations in AD
Psen1 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Psen1 Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.